Crinetics Pharmaceuticals (CRNX) Earnings Analysis

Crinetics Pharmaceuticals (CRNX) has no confirmed upcoming earnings date. Last quarter (2026-05-07) it missed with EPS -1.23 USD vs -1.22 USD est (-0.8%). It has beaten estimates in 2/6 recent quarters (33%). Trailing P/E -16.29.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does CRNX next report earnings?

No confirmed upcoming earnings date is currently scheduled for CRNX. This page updates as the calendar is published.

CRNX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-07-1.23 USD-1.22 USD-0.8%Miss
2026-02-26-1.29 USD-1.37 USD+5.8%Beat
2025-11-06-1.38 USD-1.27 USD-8.7%Miss
2025-08-07-1.23 USD-1.13 USD-8.8%Miss
2025-05-08-1.04 USD-0.99 USD-5.1%Miss
2025-02-27-0.88 USD-0.92 USD+4.3%Beat

Beat rate: 2/6 (33%) over reported quarters with consensus data.

CRNX valuation and analyst view

Trailing P/E-16.29
Trailing EPS-4.76842 USD
Price / book6.81
Dividend yield0.00%
Market cap8.88B
Analyst consensusBuy (13 buy / 7 hold / 0 sell)
Avg price target81.6 USD

Related research pages

Frequently asked questions

When is Crinetics Pharmaceuticals (CRNX)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for CRNX. This page updates as the calendar is published.

Did CRNX beat earnings last quarter?

In its 2026-05-07 report, CRNX posted EPS of -1.23 USD versus a -1.22 USD estimate — a miss of 0.8%.

What is CRNX's earnings track record?

Over the last 6 reported quarters with consensus data, CRNX beat estimates 2 times (33%).

What is CRNX's current P/E ratio and EPS?

CRNX trades at a trailing P/E of -16.29 on trailing EPS of -4.7684223671697135 USD.

What do analysts rate CRNX?

Analyst consensus is "Buy" across 20 ratings (0 strong buy, 13 buy, 7 hold, 0 sell, 0 strong sell). Average 12-month price target: 81.6 USD.